RMPs Prognostic Implications in Pts with Surgically Treated Colon Cancer
the Cancer Therapy Advisor take:
Radial margin positivity (RMP) was associated with recurrence, risk of death, shorter survival, and high rates of conversion and multivisceral resection in patients with colon cancer, according to an article published online in the journal JAMA Surgery.
The study included 984 patients with surgically treated colon cancer, excluding 47 patients with intramucosal tumors, 24 patients with palliative resections, and 16 patients with non-assessable radial margin status.
Results showed 5.3% (52 out of 984) of patients had RMP, and that these patients had increased rates of multivisceral resection (40.4% vs. 12.8%; relative risk, 3.16; 95% CI: 2.18, 4.58; P<0.001) and conversion (50.0% vs. 13.7%; relative risk, 3.78; 95% CI: 1.56, 9.18; P=0.01).
Furthermore, all patients with RMP had stage 2 cancer or higher (according to American Joint Committee on Cancer). This cohort had increased rates of node positivity (86.5% vs. 38.8%; relative risk, 2.23; 95% CI: 1.95, 2.55;<P<0.001), metastasis (34.6% vs. 6.7%; relative risk, 5.20; 95% CI: 3.34-8.11; P<0.001), extramural vascular invasion (76.9% vs. 28.4%; relative risk, 2.71; 95% CI: 2.26, 3.24; P<0.001), and high-grade tumor (45.1% vs. 18.2%; relative risk, 3.01; 95% CI: 2.44, 3.88; P<0.001).
Patients with RMP and without baseline metastasis had greater rates of metastatic disease in follow-ups (37.5% vs. 12.5%; relative risk, 3.32; 95% CI: 2.79, 3.95; P<0.001), especially metastasis of the peritoneum (18.8% vs. 2.6%; relative risk, 7.24; 95% CI: 2.40, 21.8; P<0.001) and liver (18.8% vs. 6%; relative risk, 3.10; 95% CI: 1.08, 8.92; P=0.04).
The study suggests that a timely identification of RMP in patients through preoperative assessments could lead to adequate surgical preparation and therapeutic measures.
Radial margin positivity associated with recurrence, risk of death, shorter survival in patients with colon cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Opinion: Understanding the FDA's Take on Cannabidiol
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer